ArticleWorld journal of gastrointestinal pharmacology and therapeutics2025
Odevixibat improves pruritus and bile acid level in Alagille syndrome: A case report.
Article in World journal of gastrointestinal pharmacology and therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Microbial metabolites at the nexus of gut-brain communication and neurodevelopmental disorders.Frontiers in nutrition · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlagille syndrome (ALGS) is a rare genetic disorder that affects the liver causing, cholestasis, jaundice and intractable pruritus which can significantly impair health-related quality of life (QoL). The treatment of liver involvement is mainly supportive with the majority eventually requiring liver transplant. Ileal bile acid transporter inhibition is a novel therapeutic concept for cholestatic pruritus and cholestatic liver disease. We report the effects of odevixibat treatment in a patient ALGS over 12 months. CASE SUMMARY: A male patient presented with jaundice at 3 months. ALGS was suspected clinically and genetic testing identified
conclusionThis case demonstrates the use of ileal bile acid transporter inhibitors treating pruritus and improving patient QoL. It has potential to delay the need for liver transplantation. However more long-term studies are needed to help clinicians better understand the benefit of this new treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.